Clinical partnership puts Vir Biotechnology in focus

Vir Biotechnology (VIR) has drawn fresh attention after finalizing its collaboration with Astellas Pharma on VIR-5500 for prostate cancer and treating the first patient in an expansion cohort of its Phase 1 metastatic prostate cancer trial.

The recent collaboration news comes against a backdrop of strong momentum, with a 30 day share price return of 10.49% and a year to date share price return of 68.52%. However, the 1 year total shareholder return of 77.80% contrasts with deeper 3 and 5 year total shareholder losses.

If you are looking beyond Vir Biotechnology, this is a good moment to see what else is moving in healthcare related AI by checking out 35 healthcare AI stocks

With Vir Biotechnology trading at $10.01 against an average analyst price target of $20.78 and recent returns swinging from sharp multi year losses to strong 1 year gains, is this a reset buying opportunity or is the market already pricing in future growth?

Most Popular Narrative: 52% Undervalued

Vir Biotechnology's most followed narrative points to a fair value of $20.78 versus the last close at $10.01. This frames the recent share price rebound in a very different light.

The analysts have a consensus price target of $20.78 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $17.0.

Curious why a loss making company still screens as undervalued here? The core assumptions rest on brisk revenue expansion, margin repair and a premium future earnings multiple that is far from typical for this sector.

Result: Fair Value of $20.78 (UNDERVALUED)

However, investors still face important risks, including reliance on early stage oncology data and ongoing legal disputes, such as the Brii Biosciences arbitration.

Another way to look at Vir Biotechnology's valuation

Analysts see fair value around $20.78, but the current P/S of 23.5x tells a more cautious story. It is above the US Biotechs industry at 10.8x and well above the fair ratio of 0x, even though it sits below the peer average at 30.6x. Is the stock pricing in more success than the fundamentals currently support, or are investors leaning into the oncology and hepatitis delta potential?

Next Steps

The mixed signals around Vir Biotechnology can feel confusing, so if you are watching this closely, it makes sense to act quickly and look through the full picture of risks and potential rewards for yourself by checking the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better fit your goals, risk comfort and income needs, so widen your search now.

• Target potential mispricings by scanning for quality companies trading below their estimated worth through the 51 high quality undervalued stocks.
• Strengthen your portfolio's resilience by focusing on companies with robust finances via the solid balance sheet and fundamentals stocks screener (46 results).
• Build a watchlist of tomorrow's potential standouts using the screener containing 25 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.